“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.”
Francesca Jackson-Spence, MBChB, BSc
Advertisement
Articles by Francesca Jackson-Spence, MBChB, BSc
“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
